Morningstar - Tata Consultancy Services Limited (TCS) Tata Reports Strong Start to Fiscal 2019; BFSI Recovery a Good Sign; Shares Trading at a Premium

Report

Morningstar

Andrew Lange

EUR 100.00 For Business Accounts Only

Tata Reports Strong Start to Fiscal 2019; BFSI Recovery a Good Sign; Shares Trading at a Premium

Tata Consultancy Services reported a strong start to the fiscal year. Even excluding a healthy foreign exchange tailwind during the quarter, revenue grew impressively as the firmâ€™s prior confidence in its deal pipeline came to fruition with the company seeing an important recovery in the banking, financial services, and insurance, or BFSI, business in North America. TCSâ€™ revenue growth was also buoyed by other broad-based growth in the Retail & CPG and Energy & Utilities industries. We a...

10/07/2018 12 EN

Underlying

Tata Consultancy Services Limited

Tata Consultancy Services provide consulting-led integrated portfolio of information technology (IT) and IT-enabled services delivered through a network of multiple locations around the globe. Co.'s full services portfolio consists of IT and Assurance Services, Business Intelligence and Performance Management, Business Process Services, Cloud Services, Connected Marketing Solutions, Consulting, Eco-sustainability Services, Engineering and Industrial Services, Enterprise Security and Risk Management, Enterprise Solutions, iON -Small and Medium Businesses, IT Infrastructure Services, Mobility Products and Services and Platform Solutions.

See profile

INE467B01029 National Stock Exchange of India India

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Andrew Lange

Other Reports on these Companies

Pelham Smithers Associates Ltd

PSA IT System Integrators: Whither Japanese IT Spending?

Concerns have been growing over IT spending overseas should the threat of recession materialise. But what is the situation in Japan and which system integrators are performing best? In this report we focus on NTT Data, NRI, TIS Inc and IIJ.

March 1, 2023 March 1, 2023 1 EN

Motilal Oswal

MOSL : TCS: Strong growth and demand outlook key positive in Q2

TCS: Strong growth and demand outlook key positive in Q2 (TCS IN, Mkt Cap USD138.7b, CMP INR3121, TP INR3580, 15% Upside, Buy) Stable deal TCV to allay concerns on near-term growth TCS reported revenue of USD6.87b in 2QFY23, up 4.0% QoQ in constant currency (CC) terms, 50bp above our estimates. The company reported deal wins of USD8.1b (up 7% YoY/flat QoQ, book-to-bill ratio at 1.2x), in line with its historical trajectory. EBIT improved 90bp QoQ to 24% (vs. our estimate of 23.5%) despite supply pressures. Lower employee expenses, operating leverage, and lower sub-contractor expenses aid...

EUR 120.00

October 11, 2022 October 11, 2022 12 EN

TheScreener

TATA CONSULTANCY SVS. sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of TATA CONSULTANCY SVS. (IN), a company active in the Computer Services industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date April 1, 2022, the closing price was INR 3,758.75 and its potential was estimated at INR 4,076.41.

Free Trial

April 2, 2022 April 2, 2022 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Tata Reports Strong Start to Fiscal 2019; BFSI Recovery a Good Sign; Shares Trading at a Premium

PSA IT System Integrators: Whither Japanese IT Spending?

MOSL : TCS: Strong growth and demand outlook key positive in Q2

TATA CONSULTANCY SVS. sees an upgrade to Slightly Positive due to a better fundamental star rating

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe